Preparation method for biological agent for preventing and controlling human papilloma virus infection

Abstract

The invention discloses a preparation method for a biological agent for preventing and controlling human papilloma virus infection. The preparation method includes following steps: dissolving 3-hydroxy-phthalic anhydride HP into dimethyl sulfoxide DMSO to obtain saturated HP solution; dissolving beta-lactoglobulin beta-LG into 0.1M of sodium phosphate solution with pH (potential of hydrogen) of 8.5 to obtain protein solution with protein final concentration of 20mg / mL; and equally dividing the HP solution into five parts, adding the HP solution into the protein solution at every 12 minutes, shaking and mixing, adjusting pH of IMNaOH to be 8.5, leading the final concentration of anhydride in a reaction system to be 60mM, standing for 1 hour at the temperature of 25 DEG C, dialyzing by PBS (phosphate buffer solution) with pH of 7.4, performing filtration sterilization by a 0.45uM microfiltration membrane, and storing at the temperature of 4 DEG C so as to obtain a finished product. The biological agent has the advantages of capabilities of stopping HPV (human papilloma virus) from invading cells and stopping virus infection from spreading, safety, stability, low cost and the like.

Description

technical field [0001] The invention relates to a novel antiviral biological agent in the field of medical technology, in particular to a preparation method of a biological agent for preventing and controlling human papillomavirus infection. Background technique [0002] Human papillomavirus (HPV) belongs to the papillomaviridae family (papillomaviridae), is a class of epitheliophilic non-enveloped double-stranded DNA virus. So far, the HPV isolated from human skin and mucous membrane tissue can be divided into more than 100 types according to the difference of DNA sequence. According to its carcinogenicity, it can be divided into "low risk" type and "high risk" type. The former low-risk types with high prevalence are HPV6, HPV11, etc., which mainly cause benign genital warts and low-grade cervical epithelial necrosis; the latter high-risk types with high prevalence are HPV16, HPV18, etc., and their infection is It is the main cause of tissue malignancy, especially cervica...

AI Technical Summary

Problems solved by technology

Similarly, when the virus matures, it will be released from the cells, thereby infecting new cells, causing more infections and lesions in the mouth, hands and feet, and male and female genitals, and finally leading to the expansion and deterioration of the disease, and finally the immune system cannot clear it and form a sharp Condyloma, cervical erosion, chronic cervicitis and even tumor

At present, there is still a relative lack of drugs that can effectively prevent and control HPV virus infection in the world. It is recognized that the most effective vaccines are mainly preventive vaccines. It has been clinically confirmed that HPV vaccines can almost 100% prevent some HPV virus strains from infecting, but it Does not prevent infection with all types of virus strains and is expensive

In terms of treatment, the immunomodulatory drugs used because there are no specific drugs are generally unable to effectively prevent HPV infection, have unclear curative effects, and are expensive, which greatly limits their clinical use, especially in low-income countries. developing countries

[0005] Therefore, great enthusiasm has been poured into the research and development of new drugs and biological agents that have preventive and control effects on a variety of HPV strains, but there has been no breakthrough.

Images